Vaxcyte (NASDAQ:PCVX) COO Sells $126,742.50 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50. Following the completion of the sale, the chief operating officer owned 156,760 shares in the company, valued at approximately $8,830,290.80. This trade represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00.
• On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.83, for a total value of $127,867.50.

Vaxcyte Stock Down 2.4%

Shares of NASDAQ PCVX traded down $1.43 during mid-day trading on Monday, hitting $56.96. 1,310,613 shares of the company traded hands, compared to its average volume of 1,505,627. The business has a 50 day moving average of $52.21 and a two-hundred day moving average of $53.47. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of -8.28 and a beta of 1.22. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter last year, the firm posted ($1.04) EPS. As a group, research analysts anticipate that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Finally, Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Institutional Investors Weigh In On Vaxcyte

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in Vaxcyte by 115.2% during the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock valued at $1,113,000 after buying an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Vaxcyte during the 1st quarter valued at about $219,000. Caxton Associates LLP bought a new position in shares of Vaxcyte in the 1st quarter valued at approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Vaxcyte by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after purchasing an additional 41,034 shares during the last quarter. Finally, Cetera Investment Advisers boosted its position in Vaxcyte by 13.8% during the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after purchasing an additional 932 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.